A familial C3GN secondary to defective C3 regulation by complement receptor 1 and complement factor H

Journal of the American Society of Nephrology

Volumn 27, Issue 6, 2016, Pages 1665-1677

  Chauvet, Sophie ^a,b,c   Roumenina, Lubka T ^a,b,c   Bruneau, Sarah ^d   Marinozzi, Maria Chiara ^a,b,c,e   Rybkine, Tania ^a,b,c   Schramm, Elizabeth C ^f   Java, Anuja ^f   Atkinson, John P ^f   Aldigier, Jean Claude ^g   Bridoux, Frank ^h   Touchard, Guy ^h,i   Fremeaux Bacchi, Veronique ^a,e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g LIMOGES UNIVERSITY HOSPITAL   (France)

^h Hop Pitie Salpetriere   (France)

ⁱ POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT FACTOR H; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H, HUMAN;

ADULT; ARTICLE; CASE REPORT; COMPLEMENT DEPOSITION; ELECTRON MICROSCOPY; END STAGE RENAL DISEASE; FAMILIAL DISEASE; GENE MUTATION; GLOMERULOPATHY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN PROTEIN INTERACTION; GENE EXPRESSION REGULATION; GENETICS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PEDIGREE;

ADULT; COMPLEMENT C3; COMPLEMENT FACTOR H; GENE EXPRESSION REGULATION; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; MALE; MIDDLE AGED; PEDIGREE; RECEPTORS, COMPLEMENT 3B;

EID: 85017140592     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015040348     Document Type: Article

References (59)

1. Fakhouri F, Frémeaux-Bacchi V, Noël LH, Cook HT, Pickering MC: C3 glomerulopathy: A new classification. Nat Rev Nephrol 6: 494-499, 2010
2. Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, D'Agati VD: Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int 85: 450-456, 2014
3. Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ,Medjeral-Thomas N, PaulMorgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT: C3 glomerulopathy: consensus report. Kidney Int 84: 1079-1089, 2013
4. Sethi S, Fervenza FC: Membranoproliferative glomerulonephritis-A new look at an old entity. N Engl J Med 366: 1119-1131, 2012
5. Sethi S, Fervenza FC, Zhang Y, Nasr SH, Leung N, Vrana J, Cramer C, Nester CM, Smith RJ: Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 6: 1009-1017, 2011
6. MerleNS,Church SE, Fremeaux-Bacchi V, Roumenina LT:Complement System Part I-Molecular Mechanisms of Activation and Regulation. Front Immunol 6: 262, 2015
7. Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT: Complement System Part II: Role in Immunity. Front Immunol 6: 257, 2015
8. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, Lanning L, Lutz HU, Meri S, Rose NR, Salant DJ, Sethi S, Smith RJ, Smoyer W, Tully HF, Tully SP,Walker P, WelshM, Würzner R, Zipfel PF:Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 16: 1392-1403, 2005
9. Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-DureyMA,MacherMA, Zuber J, Karras A, Provot F, Moulin B, Grünfeld JP, Niaudet P, Lesavre P, Frémeaux-Bacchi V: Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82: 454-464, 2012
10. Dragon-Durey MA, Blanc C, Marinozzi MC, van Schaarenburg RA, Trouw LA: Autoantibodies against complement components and functional consequences. Mol Immunol 56: 213-221, 2013
11. Goodship TH, Pappworth IY, Toth T, Denton M, Houlberg K, McCormick F, Warland D, Moore I, Hunze EM, Staniforth SJ, Hayes C, Cavalcante DP, Kavanagh D, Strain L, Herbert AP, Schmidt CQ, Barlow PN, Harris CL, Marchbank KJ: Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol Immunol 52: 200-206, 2012
12. Gale DP, de Jorge EG, Cook HT, Martinez-Barricarte R, Hadjisavvas A, McLean AG, Pusey CD, Pierides A, Kyriacou K, Athanasiou Y, Voskarides K, Deltas C, Palmer A, Frémeaux-Bacchi V, de Cordoba SR, Maxwell PH, Pickering MC: Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376: 794-801, 2010
13. Martínez-Barricarte R, Heurich M, Valdes-Cañedo F, Vazquez-Martul E, Torreira E, Montes T, Tortajada A, Pinto S, Lopez-Trascasa M, Morgan BP, Llorca O, Harris CL, Rodríguez de Córdoba S: Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 120: 3702-3712, 2010
14. Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V: Alternative complement pathway assessment in patients with atypical HUS. J ImmunolMethods 365: 8-26, 2011
15. Satchell SC, Tasman CH, Singh A, Ni L, Geelen J, von Ruhland CJ, O'Hare MJ, Saleem MA, van den Heuvel LP, Mathieson PW: Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF. Kidney Int 69: 1633-1640, 2006
16. Roumenina LT, Jablonski M, Hue C, Blouin J, Dimitrov JD, Dragon-DureyMA, CaylaM, FridmanWH,MacherMA, Ribes D,Moulonguet L, Rostaing L, Satchell SC, Mathieson PW, Sautes-Fridman C, Loirat C, Regnier CH, Halbwachs-Mecarelli L, Fremeaux-Bacchi V: Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 114: 2837-2845, 2009
17. Frimat M, Tabarin F, Dimitrov JD, Poitou C, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT: Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 122: 282-292, 2013
18. Marinozzi MC, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A, Cayla M, Tabarin F, Jablonski M, Hue C, Smith RJ, Noris M, Halbwachs-Mecarelli L, Donadelli R, Fremeaux-Bacchi V, Roumenina LT: Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? J AmSocNephrol 25: 2053-2065, 2014
19. Roumenina LT, Frimat M, Miller EC, Provot F, Dragon-Durey MA, Bordereau P, Bigot S,HueC, Satchell SC, Mathieson PW,MoussonC,Noel C, Sautes-Fridman C, Halbwachs-Mecarelli L, Atkinson JP, Lionet A, Fremeaux-Bacchi V: A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 119: 4182-4191, 2012
20. Forneris F, Ricklin D, Wu J, Tzekou A, Wallace RS, Lambris JD, Gros P: Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 330: 1816-1820, 2010
21. Torreira E, Tortajada A, Montes T, Rodríguez de Córdoba S, Llorca O: 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase. Proc Natl Acad Sci U S A 106: 882-887, 2009
22. Torreira E, Tortajada A, Montes T, Rodríguez de Córdoba S, Llorca O: Coexistence of closed and open conformations of complement factor B in the alternative pathway C3bB(Mg2+) proconvertase. J Immunol 183: 7347-7351, 2009
23. Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P: Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol 10: 728-733, 2009
24. Persson BD, Schmitz NB, Santiago C, Zocher G, Larvie M, Scheu U, Casasnovas JM, Stehle T: Structure of the extracellular portion of CD46 provides insights into its interactions with complement proteins and pathogens. PLoS Pathog 6: e1001122, 2010
25. Becherer JD, Lambris JD: Identification of the C3b receptor-binding domain in third component of complement. J Biol Chem263: 14586-14591, 1988
26. Janssen BJ, Gros P: Structural insights into the central complement component C3. Mol Immunol 44: 3-10, 2007
27. Oran AE, Isenman DE: Identification of residues within the 727-767 segment of human complement component C3 important for its interaction with factor H and with complement receptor 1 (CR1, CD35). J Biol Chem 274: 5120-5130, 1999
28. Farries TC, Seya T, Harrison RA, Atkinson JP: Competition for binding sites on C3b by CR1, CR2, MCP, factor B and factor H. Complement Inflamm 7: 30-41, 1990
29. Lambris JD, Lao Z, Oglesby TJ, Atkinson JP, Hack CE, Becherer JD: Dissection of CR1, factor H, membrane cofactor protein, and factor B binding and functional sites in the third complement component. J Immunol 156: 4821-4832, 1996
30. Bruneau S, Neel M, Roumenina LT, Frimat M, Laurent L, Fremeaux-Bacchi V, Fakhouri F: Loss of DGK induces endothelial cell activation and death independently of complement activation. Blood 125: 1038-1046, 2015
31. Roversi P, Johnson S, Caesar JJ, McLean F, Leath KJ, Tsiftsoglou SA, Morgan BP, Harris CL, SimRB, Lea SM: Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc Natl Acad Sci U S A 108: 12839-12844, 2011
32. Fremeaux-Bacchi V, Fakhouri F,GarnierA, Bienaimé F,Dragon-DureyMA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber J, Loirat C: Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8: 554-562, 2013
33. Frémeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL,MoghalN, Kaplan BS, Weiss RA, Lhotta K, KapurG,Mattoo T, Nivet H, Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R, Meunier V, Loirat C, Dragon-Durey MA, Fridman WH, Janssen BJ, Goodship TH, Atkinson JP:Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112: 4948-4952, 2008
34. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G: Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J AmSoc Nephrol 5: 1844-1859, 2010
35. Schramm EC, Roumenina LT, Rybkine T, Chauvet S, Vieira-Martins P, Hue C, Maga T, Valoti E, Wilson V, Jokiranta S, Smith RJH, Noris M, Goodship T, Atkinson JP, Fremeaux-Bacchi V: Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood 125: 2359-2369, 2015
36. Kazatchkine MD, Fearon DT, Appay MD, Mandet C, Bariety J: Immunohistochemical study of the human glomerular C3b receptor in normal kidney and in seventy-five cases of renal diseases: loss of C3b receptor antigen in focal hyalinosis and in proliferative nephritis of systemic lupus erythematosus. J Clin Invest 69: 900-912, 1982
37. Moll S, Lange S, Mihatsch MJ, Dragic Z, Schifferli JA, Inal JM: CRIT is expressed on podocytes in normal human kidney and upregulated in membranous nephropathy. Kidney Int 69: 1961-1968, 2006
38. Moll S, Miot S, Sadallah S, Gudat F, Mihatsch MJ, Schifferli JA: No complement receptor 1 stumps on podocytes in human glomerulopathies. Kidney Int 59: 160-168, 2001
39. Ichida S, Yuzawa Y, Okada H, Yoshioka K, Matsuo S: Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 46: 89-96, 1994
40. Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, Theis JD, Dogan A, Smith RJ: C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 82: 465-473, 2012
41. Sethi S, Gamez JD, Vrana JA, Theis JD, Bergen HR 3rd, Zipfel PF, Dogan A, Smith RJ: Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int 75: 952-960, 2009
42. Rose KL, Paixao-Cavalcante D, Fish J, Manderson AP, Malik TH, Bygrave AE, Lin T, Sacks SH,Walport MJ, Cook HT, Botto M, Pickering MC: Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest 118: 608-618, 2008
43. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G: Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8: 643-657, 2012
44. Zhang Y, Nester CM, Holanda DG, Marsh HC, Hammond RA, Thomas LJ, Meyer NC, Hunsicker LG, Sethi S, Smith RJ: Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J Am Soc Nephrol 24: 1820-1829, 2013
45. Frémeaux-Bacchi V, Weiss L, Demouchy C, May A, Palomera S, Kazatchkine MD: Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity. Nephrol Dial Transplant 9: 1747-1750, 1994
46. Blanc C, Roumenina LT, Ashraf Y, Hyvärinen S, Sethi SK, Ranchin B, Niaudet P, Loirat C,Gulati A, Bagga A, FridmanWH, Sautès-Fridman C, Jokiranta TS, Frémeaux-Bacchi V, Dragon-Durey MA: Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J Immunol 189: 3528-3537, 2012
47. Chen Q, Müller D, Rudolph B, Hartmann A, Kuwertz-Bröking E, Wu K, Kirschfink M, Skerka C, Zipfel PF: Combined C3b and factor B autoantibodies and MPGN type II. N Engl J Med 365: 2340-2342, 2011
48. Janssen BJ, Christodoulidou A, McCarthy A, Lambris JD, Gros P: Structure of C3b reveals conformational changes that underlie complement activity. Nature 444: 213-216, 2006
49. Rooijakkers SH,Wu J, Ruyken M, van Domselaar R, Planken KL, Tzekou A, Ricklin D, Lambris JD, Janssen BJ, van Strijp JA, Gros P: Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol 10: 721-727, 2009
50. Roumenina LT, Roquigny R, Blanc C, Poulain N, Ngo S, Dragon-Durey MA, Frémeaux-Bacchi V: Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS). Methods Mol Biol 1100: 237-247, 2014
51. Sánchez-Corral P, González-Rubio C, Rodríguez de Córdoba S, López-Trascasa M: Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol 41: 81-84, 2004
52. Ferreira VP, Herbert AP, Cortés C, McKee KA, Blaum BS, Esswein ST, Uhrín D, BarlowPN, PangburnMK, Kavanagh D: The binding of factorH to a complex of physiological polyanions andC3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 182: 7009-7018, 2009
53. SaleemMA,O'HareMJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P: A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 13: 630-638, 2002
54. Isenman DE, Kells DI, Cooper NR, Müller-Eberhard HJ, Pangburn MK: Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry 20: 4458-4467, 1981
55. Li K, Gor J, Perkins SJ: Self-association and domain rearrangements between complement C3 and C3u provide insight into the activation mechanism of C3. Biochem J 431: 63-72, 2010
56. Nishida N, Walz T, Springer TA: Structural transitions of complement component C3 and its activation products. Proc Natl Acad Sci U S A 103: 19737-19742, 2006
57. Pangburn MK, Schreiber RD, Müller-Eberhard HJ: Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J ExpMed 154: 856-867, 1981
58. Rodriguez E, Nan R, Li K,Gor J, Perkins SJ: A revised mechanismfor the activation of complement C3 to C3b: A molecular explanation of a disease-associated polymorphism. J Biol Chem290: 2334-2350, 2015
59. Winters MS, Spellman DS, Lambris JD: Solvent accessibility of native and hydrolyzed human complement protein 3 analyzed by hydrogen/deuterium exchange and mass spectrometry. J Immunol 174: 3469-3474, 2005